Gefitinib
Drug Details
- Description
- Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat locally advanced or metastatic non-small cell lung cancer with specific EGFR mutations.
- Alternative Names
- Gefitinib.
- Key Genes
- Key genes associated with gefitinib include EGFR (Epidermal Growth Factor Receptor). Mutations such as exon 19 deletions and exon 21 L858R substitutions in the EGFR gene are particularly relevant.
- Drug Use
- Gefitinib is primarily used for the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene.
- Genetic Factors Influencing Response
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purchase Membership to Access Your Individual Drug Response Report